The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
MedPage Today on MSN2d
IgA Nephropathy Drug With Novel Mechanism Wins FDA ApprovalThe FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...
Liberal fluid intake was safe and suggestive of better health status: this should be enough to stop restricting patients to 1 ...
PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.
The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...
People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...
Top of the agendas was chronic kidney disease (CKD), an area where Boehringer is already making an impact with blockbuster SGLT2 inhibitor Jardiance (empagliflozin). Jardiance was originally ...
"There is more work to be done to understand the mechanism of benefit as the population had a ... In both arms, about 27% of participants were receiving SGLT2 inhibitors at baseline. The mean age of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback